Description

TB-500 Research Grade Compound Handbook Product Overview

TB-500 Fragment (17-23) (Fequesetide) is the core active fragment of thymosin β -4 (sequence LKKTETQ), which binds to actin monomers with high affinity (Kd=0.3nM), activates Arp2/3 complex to enhance cell migration (rate increased by 80%), and regulates immune response (inflammation factor IL-1 β/IL-6 reduced by 40%). It significantly accelerates wound repair (shortening skin defect healing time by 6 days) and improves myocardial function (increasing ejection fraction by 18%) by promoting angiogenesis (increasing capillary density by 2.1 times) and inhibiting TGF – β 1-mediated fibrosis (reducing scar thickness by 55%), restoring muscle fiber structure to 85% normal in a muscular dystrophy model. As the first synthetic peptide targeting dynamic regulation of the cytoskeleton, it has shown potential in tissue regeneration and treatment of fibrotic diseases

main features
·   High purity: HPLC verification purity ≥ 99%
·   Research focus: TB-500 Fragment (17-23), as the core active fragment of thymosin β -4, promotes cell migration and angiogenesis by regulating actin dynamics, significantly accelerates wound repair (healing efficiency increased by 80%), inhibits inflammation and scar formation (reduced by 55%), and improves muscle function
·   Appearance: Peptide in freeze-dried (powder) form
·   Packaging specification: 10mg standard packaging (can be customized according to requirements)
·   Cold chain transportation: Ensure temperature throughout the entire process (-20 ℃)

Disclaimer: The waiver shall ensure that:
Comply with the laboratory’s “Regulations on the Management of Hazardous Chemicals” and local regulations
Established compound lifecycle tracking system
Any consequences resulting from authorized resale or non scientific use shall be borne by the user themselves